Skip to main content
SpringerLink
Log in

Fluorescence Lifetime Imaging Ophthalmoscopy in Alzheimer’s Disease

  • Chapter
  • First Online:
Fluorescence Lifetime Imaging Ophthalmoscopy

Abstract

Early pilot studies suggest that multiple FLIO-derived parameters appear to correlate with other biomarkers in patients with Alzheimer’s disease. Prolonged lifetimes in the long spectral channel was observed in early stage of Alzheimer’s disease patients, and MMSE score and CSF tau protein showed a significant correlation in advanced stage. The molecular basis and pathophysiology underlying these changes has yet to be established. Nonetheless, if these findings can be validated in future longitudinal studies, FLIO may prove to be useful as a non-invasive diagnostic tool for these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Prince PM, Ali G, Ali G. World Alzheimer report 2015. The global impact of dementia. London: Alzheimers Disease International; 2015.

    Google Scholar 

  2. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263–9. https://doi.org/10.1016/j.jalz.2011.03.005.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280–92. https://doi.org/10.1016/j.jalz.2011.03.003.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Lim YY, Maruff P, Getter C, Snyder PJ. Discloure of PET amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers Dement. 2016;12:454–8. https://doi.org/10.1016/j.jalz.2015.09.005.

    Article  PubMed  Google Scholar 

  5. Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034–42. https://doi.org/10.1212/WNL.0b013e31823b9c5e.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic nerve degeneration in Alzheimer's disease. N Engl J Med. 1986;315:485–7.

    Article  CAS  PubMed  Google Scholar 

  7. Feke GT, Hyman BT, Stern RA, Pasquale LR. Retinal blood flow in mild cognitive impairment and Alzheimer's disease. Alzheimers Dement. 2015;1:144–51. https://doi.org/10.1016/j.dadm.2015.01.004.

    Article  Google Scholar 

  8. Bambo MP, Garcia-Martin E, Pinilla J, Herrero R, Satue M, Otin S, et al. Detection of retinal nerve fiber layer degeneration in patients with Alzheimer's disease using optical coherence tomography:searching new biomarkers. Acta Ophthalmol. 2014;92:581–2. https://doi.org/10.1111/aos.12374.

    Article  CAS  Google Scholar 

  9. Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, Miller CA, Ko MK, Black KL, et al. Identification of amyloid plaques i retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. NeuroImage. 2011;54(Suppl 1):S204–17. https://doi.org/10.1016/j.neuroimage.2010.06.020.

    Article  CAS  PubMed  Google Scholar 

  10. Koronyo Y, Salumbides BC, Black KL, Koronyo-Hamaoui M. Alzheimer's disease in the retina:imaging retinal A plaques for early diagnosis and therapy assement. Neurodegener Dis. 2012;10:285–93. https://doi.org/10.1159/000335154.

    Article  CAS  PubMed  Google Scholar 

  11. Koronyo Y, Biggs D, Barron E, Boyer DS, Pearlman JA, Au WJ, Kile SJ, et al. Retinal amyloid pathology and proof-of concept imaging trial in Alzheimer's disease. JCI Insight. 2017;17:93621. https://doi.org/10.1172/jci.insight.93621.

    Article  Google Scholar 

  12. Schön C, Hoffmann NA, Ochs SM, Burgold S, Filser S, Steinbach S, et al. Long-term in vivo imaging of fibrillar tau in the retina of P301S transgenic mice. PLoS One. 2012;7:e53547. https://doi.org/10.1371/journal.pone.0053547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ho CY, Troncoso JC, Knox D, Stark W, Eberhart CG. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients. Brain Pathol. 2014;24:25–32. https://doi.org/10.1111/bpa.12070.

    Article  CAS  PubMed  Google Scholar 

  14. Jentsch S, Schweitzer D, Schmidtke KU, Peters S, Dawczynski J, Bär KJ, et al. Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer's disease. Acta Ophthalmol. 2015;93:e241–7. https://doi.org/10.1111/aos.12609.

    Article  CAS  PubMed  Google Scholar 

  15. Kwon S, Fan W, Borreli E, et al. Fluorescence lifetime imaging ophthalmoscopy in early Alzheimer’s disease patients. 2018 ARVO annual meeting.

    Google Scholar 

  16. Dysli C, Wolf S, Zinkernagel MS. Autofluorescence lifetimes in geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2016;57:2479–87. https://doi.org/10.1167/iovs.15-18381.

    Article  CAS  PubMed  Google Scholar 

  17. Bulut M, Kurtuluş F, Gözkaya O, Erol MK, Cengiz A, Akıdan M, et al. Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia. Br J Ophthalmol. 102:233. https://doi.org/10.1136/bjophthalmol-2017-310476.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Doheny Eye Institute, University of California and Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

    SriniVas R. Sadda

Authors
  1. SriniVas R. Sadda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to SriniVas R. Sadda .

Editor information

Editors and Affiliations

  1. Department of Ophthalmology and Department of Clinical Research, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland

    Martin Zinkernagel

  2. Department of Ophthalmology and Department of Clinical Research, Inselspital Bern University Hospital, University of Bern, Bern, Switzerland

    Chantal Dysli

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sadda, S.R. (2019). Fluorescence Lifetime Imaging Ophthalmoscopy in Alzheimer’s Disease. In: Zinkernagel, M., Dysli, C. (eds) Fluorescence Lifetime Imaging Ophthalmoscopy. Springer, Cham. https://doi.org/10.1007/978-3-030-22878-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-22878-1_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-22877-4

  • Online ISBN: 978-3-030-22878-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation